The National Defense Authorization Act for Fiscal Year 2017 is currently being debated in U.S. Congress. During this debate Congressman John Carter (Texas) has proposed additional controls on the use of mefloquine by the Department of Defense, and expanding the Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury‘s mission to include the study of the adverse health effects of mefloquine.
National Defense Authorization Act for Fiscal Year 2017: The House began consideration of H.R. 4909, to authorize appropriations for fiscal year 2017 for military activities of the Department of Defense and for military construction, and to prescribe military personnel strengths for such fiscal year. Consideration is expected to resume tomorrow, May 18th.
… Thornberry en bloc amendment No. 3 consisting of the following amendments printed in part B of H. Rept. 114-569:
… Carter (TX) (No. 42) that places specific reporting requirements on the Defense Department when prescribing and distributing Mefloquine to members of the Armed Forces, and requires the Secretary of Defense to conduct an annual review for each Mefloquine prescription; expands the Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury’s mission to include the study of the adverse health effects of Mefloquine …